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Abstract
Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in
overall survival in the treatment of advanced melanoma. These studies utilized two different schedules of
treatment in different patient categories (first and second line of treatment). However, the results were quite similar
despite of different dosage used and the combination with dacarbazine in the first line treatment. We reviewed
the result of randomized phase II-III clinical studies testing anti-CTLA-4 antibodies (ipilimumab and tremelimumab)
for the treatment of melanoma to focus on practical or scientific questions related to the broad utilization of these
products in the clinics. These analyses raised some considerations about the future of these compounds, their
potential application, dosage, the importance of the schedule (induction/manteinance compared to induction
alone) and their role as adjuvants. Anti-CTLA-4 antibody therapy represents the start of a new era in the treatment
of advanced melanoma but we are on the steep slope of the learning curve toward the optimization of their
utilization either a single agents or in combination.
Introduction
CTLA-4-blocking antibodies are fully human novel
monoclonal antibodies directed against CTLA-4. By
targeting CTLA-4 these antibodies prevent the inter-
action between the costimulatory molecules B7.1 an
B7.2 (CD80 and CD86) and linking to CTLA-4, thus
removing the CTLA4 inhibitory signal and releasing a
brake on the immune system. This allows a natural
immune response to react to cancer cells. The
mechanism of action of anti-CTLA-4 antibodies is
therefore indirect, through enhancing T-cell mediated
immune responses.
Two anti-CTLA-4 antibodies have been tested in
advanced clinical trials, either in phase II and phase
III: ipilimumab and tremelimumab. There is a very
small difference between the two products: both are
fully human monoclonal antibodies directed against
CTLA-4, but ipilimumab is an immunoglobulin IgG1
isotype and tremelimumab is a non-complement-fixing
IgG2 isotype.
Ipilimumab phase II studies: the assessment of
the treatment schedule
Ipilimumab has being extensively studied in different
phase II trials. In a phase II randomized study, patients
with metastatic melanoma received different doses of
ipilimumab (0.3 vs 3 vs 10 mg/kg) and the results indi-
cated a statistically significant trend of increased
response rates with increased dose, suggesting a dose-
effect [1]. Overall, most promising results in terms of
best overall response rate (BORR) were obtained with
10 mg/kg of ipilimumab, every 3 weeks for a total of 4
doses (induction phase) followed by maintenance period
in which ipilimumab was administrated every 12 weeks
(maintenance phase). This was the reason for the choice
of such a schedule for the front line phase 3 study. The
most common treatment-related adverse events (AEs)
associated with the use of ipilimumab were immune-
related and specific algorithms have been subsequently
developed, showing that early recognition and correct
therapeutic approach with steroid therapy make most of
these AEs manageable and reversible [2].
Ipilimumab phase III studies
In 2010, results from the MDX010-20 clinical trial were
published [3]. This is the first randomized phase III trial
to have demonstrated a benefit in overall survival (OS)
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study showed the superiority of ipilimumab arm com-
pared to a gp100 vaccine arm: ipilimumab monotherapy
had a median OS survival of 10.1 months whereas the
OS for gp100 monotherapy was only 6.4 months. This
clinical trial was activated in 2004, before the data from
the dose-ranging phase II randomized trial were avail-
able. It used an induction regimen of 3 mg/kg of ipili-
mumab once every 3 weeks for four administrations;
patients showing disease progression after either a stable
disease lasting more than 3 months after week 12 or a
confirmed partial or complete response were eligible for
additional courses of therapy. The safety profile in this
study was consistent with the prior studies with
ipilimumab.
On June 2011, results of a second phase III trial com-
paring dacarbazine versus dacarbazine plus ipilimumab
(CA184-024 study) in treatment naïve patients with
metastatic melanoma were published [4]. Ipilimumab
was administered at a dose of 10 mg/kg every 3 weeks
for 4 doses, followed by maintenance therapy with 10
mg/kg ipilimumab for eligible patients. This study,
although less than expected, supported the results of the
previous phase III trial by showing an OS of 11.2
months for patients treated with dacarbazine plus ipili-
mumab and an OS of 9.1 months for patients treated
with dacarbazine alone.
Ipilimumab efficacy: Optimal dose and schedule
Even if they are not directly comparable, given the dif-
ferences in study design, by looking at the survival
curves of the two phase III trials [3,4] they appear to be
quite similar (Figure 1), although there is less evidence
of a tail of the curve of long term durable responses in
the trial combining ipilimumab with dacarbazine. This
raises some questions about which are the best dosage
(3 vs 10 mg/kg), the best schedule (re-induction vs
maintenance) and the combination with chemotherapy.
Another question concerns the role of dacarbazine
regarding combination regimes and toxicity profile,
since in the dacarbazine plus ipilimumab arm hepato-
toxicity appeared to be higher than in the control arm
(31,6% vs 2,4% of grade 3/4) and higher than with the
prior experience with single agent ipilimumab at 3 or 10
mg/kg. In this regard, results from another combination
trial with fotemustine could give us more information
about efficacy and safety of combination regimens with
cytotoxic chemotherapy [5].
Optimal dose
Regarding the best dose between 3 and 10 mg/kg, on
the base of effect-response analysis in phase II and
phase III studies, it is not fully elucidated if the dose of
3 mg/kg ipilimumab is the optimal one. Certainly, taking
into account data coming from the expanded access
program (EAP), 3 mg/kg seems to be sufficient to be
clinically effective and does not seem to be burdened by
excessive toxicity [6]. Nevertheless, in the CA184-024
study the used ipilimumab dose was 10 mg/kg and, in
the dacarbazine plus ipilimumab arm, only 93 patients
(36,8%) completed all four induction cycles. Therefore,
no conclusion about which is the best regimen can be
drawn at the present moment. An upcoming rando-
mized trial will directly compare 3 mg/kg versus 10 mg/
MDX010-020 study 
modified from Hodi et al. N Engl J Med. 20103 
Ca184-024 study 
modified from Robert et al. N Engl J Med. 20114 
Figure 1 Comparison between the Overall Survival curves of the studies MDX010-20 and CA184-024.
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will probably help us to answer the question about effi-
cacy in terms of OS and safety of the two regimens.
It is also clear that the two schedules have different
safety profiles. The incidence of severe (grade 3-4)
adverse events (AEs) in the 3 mg/kg schedule was 10-
15%, while in the ipilimumab combination arm of the
CA184-024 study was 56.3% (41.7% was severe
immuno-related AEs, irAEs). It is also clear that in the
future we will need to monitor the incidence of severe
irAE even considering new possible toxicities (neutrope-
nia, thrombocytopenia) [7,8] because the early recogni-
tion and treatment is mandatory to reduce the risk of
sequelae for patients.
Maintenance or re-induction?
One of the main points to be clarified is the optimal
treatment schedule and the role of re-induction or
maintenance. In fact, in the first line clinical trial only
43 patients (17.2%) received at least one dose of mainte-
nance treatment, while in the second line trial just 7%
of patients received at least one re-induction dose.
Moreover, if the true value of maintenance remains to
be defined, the utility of reinduction has been studied.
In the MDX010-20 study [3], 21 out of 31 (68%)
patients who received reinduction with ipilimumab had
ar e s p o n s eo rad u r a b l eS Dw i t hr e i n d u c t i o nw i t h o u t
significant additional toxicities. Therefore, it remains to
be defined whether 4 cycles are sufficient in terms of
efficacy and whether re-induction or maintenance do
add anything in terms of efficacy or could alternatively
worsen toxicities.
Additional evidence regarding the utility of reinduc-
tion is derived from the MDX010-08 trial which com-
pared ipilimumab alone (3 mg/kg for 4 cycles schedule)
versus ipilimumab in combination with dacarbazine [9].
In this trial, patients who progressed on monotherapy
could cross-over and receive combination therapy upon
progression, but none of the patients treated with the
cross-over had a response. Moreover, in this trial the
BORR and the disease control rate (DCR) (see table 1)
was quite similar to the phase III studies: in the ipilimu-
mab alone arm, the BORR was 5.4% and the DCR was
21.6% (the BORR and DCR of the ipilimumab plus
gp100 arm in MDX010-20 study was respectively 5.7%
and 20.1%) [3]; while, in the dacarbazine plus ipilimu-
mab combination arm, the BORR was 14.3% and the
DCR was 37.1% (the BORR and DCR of the dacarbazine
plus ipilimumab arm in the CA184-024 study was
respectively 15.2% and 33.2%) [4].
Evaluation of response
Another important issue concerns how to evaluate the
response to anti-CTLA-4 therapy. In fact, if prolonga-
tion of survival is a clear fact, it still remains unsolved
the problems of response evaluation. In fact, the main
difficulty for several oncologists without experience in
immunotherapy will be the evaluation of response in
patients treated with ipilimumab. As described, ipilimu-
mab doesn’t impact on PFS and BORR. For this reason
could be difficult to take a decision, for an oncologist, at
the time of the first assessment (normally oncologist
retain that the week 12 represent the best time for this).
Immuno-related response criteria (irRC) could help
oncologists in evaluating the response to ipilimumab.
However, it remains not easy to perform an assessment
when it’s not clearly evident a response and considering
the limited percentage of complete and partial response.
For this reason, it merits a comment the study design
of the EORTC18071, an ongoing study on ipilimumab
in the adjuvant setting. The primary endpoint of such
trial, is relapse-free survival (RFS) and the used dose is
10 mg/kg with induction and 3-years maintenance. This
study underlines the above consideration that, if the
Table 1 Comparison among the Best Overall Response Rate, the Disease Control Rate, and the duration of response of
the three randomized phase II-III studies which utilized ipilimumab (MDX010-08, MDX010-20, and CA184-024)
MDX010-08 MDX010-20 CA184-024
DTIC + Ipi Ipi Ipi + gp100 Ipi gp100 DTIC + Ipi DTIC
Patients (N.) (35) (37) (403) (137) (136) (250) (252)
BORR 14.3% 5.4% 5.7% 10.9% 1.5% 15.2% 10.3%
DCR 37.1% 21.6% 20.1% 28.5% 11.0% 33.2% 30.1%
Median Duration of BOR in months (CI) 5.7*
(0.7-19.2)
10.8*
(3.0-25.4)
11.5
(5.5-NR)
NR
(28.1-NR)
NR
(2.0-NR)
19.3
(not reported)
8.1
(not reported)
*this value indicated the major durable DCR (≥ 24 weeks)
DTIC = dacarbazine
Ipi = ipilimumab
BORR = Best Overall Response Rate = Complete Remission + Partial Remission
DCR = Disease Control Rate = Complete Remission + Partial Remission + Stable Disease
BOR = Best Overall Response
CI = Confidence Interval
NR = Not Reached
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of OS, so it cannot be said if we consider the surrogates
(BORR and DFS). Moreover, while in the MDX010-20
trial both BORR and PFS are statistically significant in
the ipilimumab arms, in the CA184-024 trial progres-
sion free survival (PFS) is similar in the two arms. Is it
therefore RFS the best way to show efficacy of ipilimu-
mab in the adiuvant setting? Probably not, but at the
moment it is not easy to find a valid surrogate for OS.
The duration of response is another important para-
meter. In table 1 we summarized the results in the three
randomized phase II-III trial. It’s clear enough that ipili-
mumab gives durable response.
The Tremelimumab experience
With regard to the other anti-CTLA-4 antibody tremeli-
mumab, treatment schedule of 15 mg/kg every 90 days
was defined in different phase I/II studies [10,11] and
therefore tested in a phase III trial versus chemotherapy
control arm (dacarbazine or temozolomide) [12]. The 15
mg/kg dosing regimen every 90 days was chosen based
on the results of a prior phase 2 randomized clinical
trial comparing this dosing regimen with tremelimumab
at 10 mg/kg administered monthly; results of response
rate, PFS and OS was similar in both arms, while the
safety profile favored the 15 mg/kg every 90 days dosing
regimen [10]. Unfortunately, differences in OS in the
phase 3 trial were not statistically significant with 11.76
months in the tremelimumab arm versus 10.71 months
in the control arm. One of the reason could be the
treatment schedule every 90 days, However, this is unli-
kely since comparison of the response rates (assessed by
independent radiology review committees) between the
two phase 2 single arm studies of ipilimumab at 10 mg/
kg every 3 weeks and tremelimumab at 15 mg/kg every
90 days demonstrate (with the caveats of cross-study
comparisons) very similar response and toxicity results
[11,13]. Another possibility is that the restriction of the
LDH level to up to twice the upper limit of normality in
the tremelimumab phase 3 trial resulted in an advantage
for the control arm that was not present in the ipilimu-
mab phase 3 trials that did not have this restriction.
More likely, the concurrent availability of ipilimumab in
several studies that did not exclude prior anti-CTLA4-
based therapies (including two expanded access proto-
cols) allowed a significant cross-over to ipilimumab in
patients randomized to the control arm of the tremeli-
mumab phase 3 trial. Since the ipilimumab studies were
blinded and all the tremelimumab studies excluded
patients who had been previously enrolled in a study
including an anti-CTLA4 antibody, cross-over to treme-
limumab in the ipilimumab control arms was less likely.
Identification of responder patients
An important challenge for the future will be the identi-
fication of patients who are more likely to respond to
anti-CTLA4 treatment. It has been suggested that the
absolute lymphocyte count (ALC) ≥ 1000/μL after 2 ipi-
limumab treatments (week 7 )c o u l db eap o s s i b l em a r -
ker and seems to correlate with clinical benefit and OS
[14]. Another important biomarker could be the expres-
sion of the inducible costimulator (ICOS) molecule
[15-17], a member of the immunoglobulin gene family,
on T cells. ICOS was shown to correlate with clinical
outcome in a small cohort of melanoma patients treated
with ipilimumab [18] and to be necessary for optimal
anti-tumor responses mediated by anti-CTLA-4 [19].
Other potential biomarkers could be the mean rate of
CD8 change, the resistance of CD4+ T cells to Treg
mediated inhibition in vitro, and the frequency of IL-17
secreting CD4+ T cells [20]. Even biomarkers in the
tumor microenvironment have been demonstrated to be
associated with clinical activity in patients treated with
ipilimumab [21]. In fact, it was showed that clinical
activity was related with high expression of FOXP3 and
IDO at baseline and an increase from baseline in tumor-
infiltrating lymphocytes (TILs) (Wk 4) in tumor biop-
sies. However, further studies should be designed to
evaluate these biological endpoints and provide prospec-
tive validation.
Conclusion
For more than 30 years we have been waiting for
advances in the therapy of patients with advanced mela-
noma, while just over the last 2 years we have witnessed
a real revolution. If ipilimumab can rightly be consid-
ered a cornerstone of a new era in cancer treatment,
there is still a lot to be done to optimize the therapy
with anti-CTLA-4 antibodies, especially to define the
best schedule for next combination regimens (immuno-
modulatory antibodies, BRAF/MEK inhibitors, vaccines,
etc.) which represent the natural evolution of future
melanoma therapy [22].
Author details
1Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale
Tumori Fondazione Pascale, Naples, Italy.
2Infectious Diseases and
Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical
Center and Center for Human Immunology (CHI), NIH, Bethesda, Maryland,
USA.
3Department of Medicine, Jonsson Comprehensive Cancer Center at
the University of California Los Angeles (UCLA), Los Angeles, California, USA.
Authors’ contributions
All Authors: 1) made intellectual contributions and participated in the
acquisition, analysis and interpretation of data; 2) have been involved in
drafting the manuscript; and 3) have given final approval of the version to
be published.
Ascierto et al. Journal of Translational Medicine 2011, 9:196
http://www.translational-medicine.com/content/9/1/196
Page 4 of 5Competing interests
PAA participated to Advisory Board from Bristol Myers Squibb, Merck Sharp
& Dohme, Roche-Genentech, GSK and received honoraria from Bristol Myers
Squibb, Roche Genentech and Merck Sharp & Dohme; FM has no conflict of
interest; AR received honoraria from Bristol Myers Squibb and was
Consultant for Amgen, Merck, Roche-Genentech.
There are no financial disclosure and acknowledgements
Received: 9 November 2011 Accepted: 13 November 2011
Published: 13 November 2011
References
1. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W,
Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K,
Hoos A, O’Day SJ, Lebbé C: Ipilimumab monotherapy in patients with
pretreated advanced melanoma: a randomised, double-blind,
multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-64.
2. Lin R, Yellin MJ, ILowy I, Safferman A, Chin K, Ibrahim R: An analysis of the
effectiveness of specific guidelines for the management of ipilimumab-
mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/
or colectomy [2008 ASCO Meeting abstract 9063]. J Clin Oncol 2008,
26:9063.
3. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den
Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D,
Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS,
Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with
ipilimumab in patients with metastatic melanoma. N Engl J Med 2010,
363:711-23.
4. Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C,
Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A,
Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S,
Chen TT, Humphrey R, Hoos A, Wolchok JD: Ipilimumab plus dacarbazine
for previously untreated metastatic melanoma. N Engl J Med 2011,
364:2517-26.
5. Di Giacomo AM, Ascierto PA, Fonsatti E, Pittiglio E, Queirolo P, Pilla L,
Ridolfi R, Santinami M, Testori A, Parmiani G, Maio M: A phase II study
combining ipilimumab and fotemustine in patients with metastatic
melanoma: The NIBIT-M1 trial. [2011 ASCO Meeting abstract TPS230]. J
Clin Oncol 2011, 29:TPS230.
6. Simeone E, Gentilcore G, Esposito A, Curvietto M, De Rosa P, De Maio E,
Pistillo MP, Queirolo P, Mozzillo N, Ascierto PA: Immunological and
biological changes and their correlation with Clinical Response and
Survival during Ipilimumab in metastatic melanoma Compassionate Use
Program [2011 ESMO Meeting abstract 9322]. Eur J Cancer 2011, 47(suppl
1):686.
7. Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE,
Arellano ML: Neutropenia in a patient treated with ipilimumab (anti-
CTLA-4 antibody). J Immunother 2009, 32:322-4.
8. Ahmad S, Lewis M, Corrie P, Iddawela M: Ipilimumab-induced
thrombocytopenia in a patient with metastatic melanoma. J Oncol
Pharm Pract 2011, PubMed PMID: 21807763.
9. Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD,
Samlowski WE, Nichol GM, Yellin MJ, Weber JS: A phase II multicenter
study of ipilimumab with or without dacarbazine in chemotherapy-naïve
patients with advanced melanoma. Invest New Drugs 2011, 29:489-98.
10. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B,
Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A: Phase I/II trial
of tremelimumab in patients with metastatic melanoma. J Clin Oncol
2009, 27:1075-81.
11. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D,
Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA: Phase II trial of
tremelimumab (CP-675,206) in patients with advanced refractory or
relapsed melanoma. Clin Cancer Res 2010, 16:1042-8.
12. Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C,
Gomez-Navarro J, Pavlov D, Marshall M: Phase III, open-label, randomized,
comparative study of tremelimumab (CP-675,206) and chemotherapy
(temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced
melanoma [2008 ASCO Meeting abstract LBA9011]. J Clin Oncol 2008, 26:
LBA9011.
13. O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H,
Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L,
Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD:
Efficacy and safety of ipilimumab monotherapy in patients with
pretreated advanced melanoma: a multicenter single-arm phase II study.
Ann Oncol 2010, 21:1712-7.
14. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD,
Chapman PB, Schwartz GK, Allison JP, Wolchok JD: Single-institution
experience with ipilimumab in advanced melanoma patients in the
compassionate use setting: lymphocyte count after 2 doses correlates
with survival. Cancer 2010, 116:1767-75.
15. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R,
Anagnostopoulos I, Kroczek RA: ICOS is an inducible T-cell co-stimulator
structurally and functionally related to CD28. Nature 1999, 397:263-6.
16. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C,
Sharma P: CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi
cells to shift the ratio of effector to regulatory T cells in cancer patients.
Proc Natl Acad Sci USA 2008, 105:14987-92.
17. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D,
Dorazio P, Trosko JA, Rüter J, Mariani GL, Usari T, Domchek SM:
Tremelimumab in combination with exemestane in patients with
advanced breast cancer and treatment-associated modulation of
inducible costimulator expression on patient T cells. Clin Cancer Res 2010,
16:3485-94.
18. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G,
Troncoso P, Logothetis CJ, Allison JP, Sharma P: Preoperative CTLA-4
blockade: tolerability and immune monitoring in the setting of a
presurgical clinical trial. Clin Cancer Res 2010, 16:2861-71.
19. Fu T, He Q, Sharma P: The ICOS/ICOSL pathway is required for optimal
antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011,
71:5445-54.
20. Callahan MK, Wolchok JD, Allison JP: Anti-CTLA-4 antibody therapy:
immune monitoring during clinical development of a novel
immunotherapy. Semin Oncol 2010, 37:473-84.
21. Hamid O, Chasalow SD, Tsuchihashi Z, Alaparthy S, Galbraith S, Berman D:
Association of baseline and on-study tumor biopsy markers with clinical
activity in patients (pts) with advanced melanoma treated with
ipilimumab [2009 ASCO Meeting abstract 9008]. J Clin Oncol 2009,
27:9008.
22. Ascierto PA, Streicher HZ, Sznol M: Melanoma: a model for testing new
agents in combination therapies. J Transl Med 2010, 8:38.
doi:10.1186/1479-5876-9-196
Cite this article as: Ascierto et al.: Anti-CTLA4 monoclonal antibodies:
the past and the future in clinical application. Journal of Translational
Medicine 2011 9:196.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ascierto et al. Journal of Translational Medicine 2011, 9:196
http://www.translational-medicine.com/content/9/1/196
Page 5 of 5